Patents by Inventor Holger Andreas Russ

Holger Andreas Russ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11332716
    Abstract: Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 17, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Matthias Hebrok, Holger Andreas Russ, Sheng Ding, Saiyong Zhu
  • Patent number: 11299711
    Abstract: Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into the mature beta cells of enriched beta clusters, wherein the beta cells rapidly and reliably secrete insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals. These cells can also be used for drug screening purposes to identify factors/chemicals capable of increasing beta cell functions, proliferation, survival, and resistance to immune assault.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: April 12, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Matthias Hebrok, Holger Andreas Russ, Gopika G. Nair
  • Patent number: 10975355
    Abstract: Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into pancreatic beta-like cells secreting insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Matthias Hebrok, Holger Andreas Russ
  • Publication number: 20190177697
    Abstract: Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into the mature beta cells of enriched beta clusters, wherein the beta cells rapidly and reliably secrete insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals. These cells can also be used for drug screening purposes to identify factors/chemicals capable of increasing beta cell functions, proliferation, survival, and resistance to immune assault.
    Type: Application
    Filed: April 7, 2017
    Publication date: June 13, 2019
    Inventors: Matthias Hebrok, Holger Andreas Russ, Gopika G. Nair
  • Publication number: 20180216076
    Abstract: Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 2, 2018
    Inventors: Matthias Hebrok, Holger Andreas Russ, Sheng Ding, Saiyong Zhu
  • Publication number: 20180087034
    Abstract: Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into pancreatic beta-like cells secreting insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals.
    Type: Application
    Filed: April 22, 2016
    Publication date: March 29, 2018
    Inventors: Matthias Hebrok, Holger Andreas Russ